A-HeFT: Old dog, new endothelial tricks

In conclusion, reduced nitric oxide bioactivity contributes to cardiac and vascular remodeling. Nitric-oxide-enhancing therapy can slow cardiac and vascular remodeling. African-Americans with heart failure exhibit nitric oxide deficiency and a dramatic benefit from nitric-oxide-enhancing therapy. The potential benefit of this therapy in other groups with heart failure and in other vascular remodeling disease processes requires further study.